Board of Directors

Board of Directors

Members of the Cyxone board have extensive experience of taking projects from academic research stage to publicly traded development companies, fundraising as well as negotiating license and cooperation agreements.

Bert Junno

Chairman of the Board

Born 1966. Chairman of the Board since 2015.

Experiences

Dr Junno has previous management and board level experience from several European and US based companies in fields of electronics, biotech and IT. He has also co-founded several life science companies, for example WntResearch AB (publ), Galecto Biotech AB, Gabather AB (publ), Aptahem AB (publ) and Cyxone AB (publ). Dr Junno holds a Ph.D. in Semiconductor Physics and Technology and a M.Sc. in Physics from Lund University.

Other assigments

  • Chairman of the Board in CombiGene AB (publ)
  • Chairman of the Board in Aptahem AB (publ)
  • Board Member in Accequa AB
  • Board Member in Accequa GmbH

Previous assignments

  • Board Member in Gabather AB (publ)
  • Board Member in Gabather Finans AB
  • CEO in Gabather AB (publ)
  • Member of the Advisory Board of the Swedish Intellectual Property Office

Shares in the company

Bert Junno owns 400,000 shares in Cyxone. Junno further owns 1,788,732 shares in Cyxone through Fornio AB.

Theresa Comiskey Olsen

Board Member

Born 1963. Board Member since 2016.

Experiences

Theresa Comiskey Olsen, Attorney at Law (USA), is associated with Albaran, a Norwegian law firm. Over the past several years Comiskey Olsen has developed her law practice with particular focus on cross-border transactions in the Life Sciences/Biotech/Pharma/Medtech fields, with special emphasis on negotiating and drafting international licensing, distribution, supply, research and development, and clinical trial agreements. Prior to starting her practice in 2008, she was General Counsel of Nycomed, which has since been acquired by Takeda. Comiskey Olsen has her B.A. from University of Pennsylvania and her J.D. from University of Detroit Mercy School of Law.

Other assignments

  • Board Member in FF Bygg og Vedlikehold AS
  • Board Member in Jotunfjell AS
  • Board Member in Aptahem AB (publ)
  • Board Member in Farma Investment AS
  • Owner Comiskey Olsen

Previous assignments

  • Board Member in PCI Biotech Holding ASA
  • Board Member in Calpro AS
  • Board Member in Nordic Nanovector ASA
  • Board Member in Serodus ASA
  • Board Member in Biovotec AS
  • Owner and partner in Langseth Advokatfirma DA
  • Chairman of the Board in MyLifeProducts AS
  • Owner and partner in Advokatfirmaet Nova DA

Shares in the company

Theresa Comiskey Olsen owns 100,000 shares in Cyxone

Saad Gilani

Board Member

Born 1971. Board Member since 2015.

Experiences

Saad Gilani is currently a Managing Director at Yorkville Advisors Global, a member of the company’s investment committee and a board member of Temple Therapeutics BV. As head of the Healthcare Group, he has led financing transactions in a variety of life science companies focusing on biotechnology, molecular diagnostics and medical equipment in the United States and Europe. Prior to joining Yorkville Advisors Global, Saad worked at Keyence Corporation for 11 years in engineering and marketing. He holds a Bachelor in Electrical Engineering from Rutgers College of Engineering and MBA from Rutgers University in New Jersey, where he specialized in finance.

Other assignments

  • Board Member in Temple Therapeutics BV

Shares in the company

Saad Gilani owns 132,500 shares in Cyxone

Mikael Lindstam

Board Member

Born 1966. Board Member since 2015.

Experiences

Mikael has 20 years’ experience in the Swedish start-up industry, during which he has been instrumental in the founding and development of Galecto Biotech, Cyxone, Gabather, Aptahem and nanotechnology companies, Portendo, NM Spintronics and Serstech as founder. Mikael’s contributions have generated investments of over €70M from business, private and public capital. Mikael has solid experience as a manager and board member in public companies, including responsibilities in company management, IPR, fundraising, negotiations and business development activities. In 2008-2014, Mikael was co-managing a Governmental investment fund focusing on life science and drug projects with strong IPR backbone and market potential. There, Mikael managed over 100 different assets which were capitalized though spin-outs, out-licensing and acquisitions. Accequa AB and Accequa GmbH are two investment vehicles for early stage life science assets where Mikael is a founder. Mikael holds a PhD in Inorganic Chemistry from Uppsala University and has Individual diplomas from programs in People Management, Coaching, Business and Project Development and Administration, Entrepreneurship, Marketing and Stock market ethics.

Other assignments

  • CEO of Aptahem AB
  • Chairman of the board in Accequa AB
  • Board Member in Aptahem Finans AB
  • Board Member in Accequa GmbH
  • Owner Mikeoo Holding AB
  • Owner Holy Plantmedix AB

Previous assignments

  • Board Member in Ceratmo AB
  • Board Member in Aptahem AB

Shares in the company

Mikael Lindstam owns 62,500 shares in Cyxone. Lindstam further owns 1,788,732 shares in Cyxone through Mikeoo Holding AB.